What is it about?
Complete remission of severe thyroid opthalmopathy after the use of a chimeric monoclonal antibody against the protein CD20 ( rituximab)
Featured Image
Why is it important?
It is two of the few cases of sight threatening Graves; disease that reacted with full remission after the administration of rituximab and had no relapses after two years of follow up
Read the Original
This page is a summary of: Enduring remission of active and sight-threatening Graves’ orbitopathy with rituximab: report of two cases, Endocrine Journal, January 2018, Japan Endocrine Society,
DOI: 10.1507/endocrj.ej18-0074.
You can read the full text:
Contributors
The following have contributed to this page
